We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Secukinumab 300 mg administered with an auto-injector ...

SAN DIEGO — For patients with active psoriatic arthritis, the human interleukin (IL)-17A antagonist secukinumab (Cosentyx, Novartis Pharmaceuticals), administered by subcutaneous injection, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SAN DIEGO — An intravenous formulation of secukinumab ...

Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old. The FDA has approved ...

LONDON -- The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) was clearly effective in treating polymyalgia rheumatica (PMR) in a phase III trial, researchers reported, even as they also ...

The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older ...

Treatment with interleukin (IL)-17A inhibitor secukinumab as first-line monotherapy for concomitant moderate to severe plaque psoriasis and active psoriatic arthritis (PsA) was associated with higher ...

The results from an analysis of patients from 12 rheumatology centers treated with secukinumab for psoriatic arthritis were in line with earlier pivotal trials, the researchers said. A recent study of ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

psoriasis-Secukinumab-1114 All subjects successfully self-administered treatment at Week 1, without critical use-related hazards. Secukinumab, a drug currently in clinical trials for treatment of ...